[1,1':2',1''-terphenyl]-3'-ylmethanol

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: [1,1':2',1''-terphenyl]-3'-ylmethanol
• 英文别名: (2,3-Diphenylphenyl)methanol
• 化学式: C₁₉H₁₆O
• 分子量: 260.335
• InChiKey: OYZJTOQNINWGDU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  [1,1':2',1''-terphenyl]-3'-ylmethanol 在 氯化亚砜 、 potassium carbonate 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 4-([1,1′:2′,1″-terphenyl]-3′-ylmethoxy)-3-bromobenzaldehyde
  参考文献：
  名称：

  Di-bromo-Based Small-Molecule Inhibitors of the PD-1/PD-L1 Immune Checkpoint

  摘要：

  Immune checkpoint blockade is one of the most promising strategies of cancer immunotherapy. However, unlike classical targeted therapies, it is currently solely based on expensive monoclonal antibodies, which often inflict immune-related adverse events. Herein, we propose a novel small-molecule inhibitor targeted at the most clinically relevant immune checkpoint, PD-1/PD-L1. The compound is capable of disrupting the PD1/PD-L1 complex by antagonizing PD-L1 and, therefore, restores activation of T cells similarly to the antibodies, while being cheap in production and possibly nonimmunogenic. The final compound is significantly smaller than others reported in the literature while being nontoxic to cells even at high concentrations. The scaffold was designed using a structure-activity relationship screening cascade based on a new antagonist-induced dissociation NMR assay, called the weak-AIDA-NMR. Weak-AIDA-NMR finds true inhibitors, as opposed to only binders to the target protein, in early steps of lead compound development, and this process makes it less time and cost consuming.

  DOI：

  10.1021/acs.jmedchem.0c01260
• 作为产物：
  描述：

  2,3-二溴苯甲酸 在 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 硼烷四氢呋喃络合物 、 potassium carbonate 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 水 为溶剂， 反应 28.0h， 生成 [1,1':2',1''-terphenyl]-3'-ylmethanol
  参考文献：
  名称：

  Di-bromo-Based Small-Molecule Inhibitors of the PD-1/PD-L1 Immune Checkpoint

  摘要：

  Immune checkpoint blockade is one of the most promising strategies of cancer immunotherapy. However, unlike classical targeted therapies, it is currently solely based on expensive monoclonal antibodies, which often inflict immune-related adverse events. Herein, we propose a novel small-molecule inhibitor targeted at the most clinically relevant immune checkpoint, PD-1/PD-L1. The compound is capable of disrupting the PD1/PD-L1 complex by antagonizing PD-L1 and, therefore, restores activation of T cells similarly to the antibodies, while being cheap in production and possibly nonimmunogenic. The final compound is significantly smaller than others reported in the literature while being nontoxic to cells even at high concentrations. The scaffold was designed using a structure-activity relationship screening cascade based on a new antagonist-induced dissociation NMR assay, called the weak-AIDA-NMR. Weak-AIDA-NMR finds true inhibitors, as opposed to only binders to the target protein, in early steps of lead compound development, and this process makes it less time and cost consuming.

  DOI：

  10.1021/acs.jmedchem.0c01260

文献信息

• A LIQUID CRYSTAL LAYER INCLUDING A DICHROIC DYE
  申请人：——

  公开号：US20020005930A1

  公开（公告）日：2002-01-17

  A reflecting film is formed on one of the substrates, and a ¼ wavelength layer is arranged on this reflecting film. A liquid crystal layer comprises liquid crystal molecule, a polymer and dichroic dye, the polymer particles being dispersed in liquid crystal molecules. Using this configuration, a liquid crystal apparatus free from parallax is available. Because the dichroic dye is mixed in the liquid crystal layer, a light entering the liquid crystal layer upon non-application of voltage is absorbed by the dichroic dye, thus giving a light absorbing state. Upon application of voltage, there is available a light scattering state.

  在其中一块基板上形成反射膜，并在该反射膜上布置 ¼ 波长层。液晶层由液晶分子、聚合物和二色性染料组成，聚合物颗粒分散在液晶分子中。利用这种结构，可以获得无视差的液晶装置。 由于在液晶层中混有二色性染料，在不施加电压的情况下，进入液晶层的光线会被二色性染料吸收，从而呈现出光吸收状态。在施加电压时，则出现光散射状态。
• US4118487A
  申请人：——

  公开号：US4118487A

  公开（公告）日：1978-10-03
• Di-bromo-Based Small-Molecule Inhibitors of the PD-1/PD-L1 Immune Checkpoint
  作者：Magdalena Konieczny、Bogdan Musielak、Justyna Kocik、Lukasz Skalniak、Dominik Sala、Miroslawa Czub、Katarzyna Magiera-Mularz、Ismael Rodriguez、Maja Myrcha、Malgorzata Stec、Maciej Siedlar、Tad A. Holak、Jacek Plewka

  DOI：10.1021/acs.jmedchem.0c01260

  日期：2020.10.8

  Immune checkpoint blockade is one of the most promising strategies of cancer immunotherapy. However, unlike classical targeted therapies, it is currently solely based on expensive monoclonal antibodies, which often inflict immune-related adverse events. Herein, we propose a novel small-molecule inhibitor targeted at the most clinically relevant immune checkpoint, PD-1/PD-L1. The compound is capable of disrupting the PD1/PD-L1 complex by antagonizing PD-L1 and, therefore, restores activation of T cells similarly to the antibodies, while being cheap in production and possibly nonimmunogenic. The final compound is significantly smaller than others reported in the literature while being nontoxic to cells even at high concentrations. The scaffold was designed using a structure-activity relationship screening cascade based on a new antagonist-induced dissociation NMR assay, called the weak-AIDA-NMR. Weak-AIDA-NMR finds true inhibitors, as opposed to only binders to the target protein, in early steps of lead compound development, and this process makes it less time and cost consuming.